Table 2.
Baseline tumour and patient characteristics per primary treatment (PET or surgery)a.
| PET in Age Gap |
PET in Climb |
Surgery in Age Gap |
Surgery in Climb |
p-value | |||||
|---|---|---|---|---|---|---|---|---|---|
| N = 474 |
N = 39 |
N = 2375 |
N = 494 |
||||||
| n | (%) | n | (%) | n | (%) | n | (%) | ||
| Age | N = 474 | N = 39 | N = 2374 | N = 494 | <0.001 | ||||
| 70-74 | 58 | (12.2) | 1 | (2.6) | 1009 | (42.5) | 253 | (51.2) | |
| 75-59 | 90 | (19.0) | 5 | (12.8) | 750 | (31.6) | 111 | (22.5) | |
| 0-84 | 126 | (26.6) | 11 | (28.2) | 431 | (18.2) | 90 | (18.2) | |
| ≥85 | 200 | (42.2) | 22 | (56.4) | 184 | (7.8) | 40 | (8.1) | |
| Median (IQR) | 83.0 | (78.0–87.3) | 86.0 | (82.0–90.0) | 76.0 | (72.0–80.0) | 74.0 | (72.0–80.0) | <0.001 |
| Tumour grade | N = 457 | N = 8 | N = 2366 | N = 479 | <0.001 | ||||
| Grade I | 97 | (21.2) | 0 | (0.0) | 409 | (17.3) | 133 | (27.8) | |
| Grade II | 302 | (66.1) | 3 | (37.5) | 1557 | (65.8) | 228 | (47.6) | |
| Grade III | 58 | (12.7) | 5 | (62.5) | 400 | (16.9) | 118 | (24.6) | |
| Tumour sizeb | N = 463 | N = 36 | N = 2374 | N = 488 | <0.001 | ||||
| 0–2 CM | 222 | (47.9) | 11 | (30.6) | 1499 | (63.1) | 333 | (68.2) | |
| 2–5 CM | 230 | (49.7) | 21 | (58.3) | 809 | (34.1) | 131 | (26.8) | |
| >5CM | 11 | (2.4) | 4 | (11.1) | 66 | (2.8) | 24 | (4.9) | |
| Nodal statusb | N = 470 | N = 31 | N = 2374 | N = 469 | 0.469 | ||||
| Node-negative | 393 | (83.6) | 25 | (80.6) | 2039 | (85.9) | 396 | (84.4) | |
| Node-positive | 77 | (16.4) | 6 | (19.4) | 335 | (14.1) | 73 | (15.6) | |
| Charlson Comorbidity Index | N = 474 | N = 39 | N = 2375 | N = 494 | <0.001 | ||||
| 0 | 171 | (36.1) | 8 | (20.5) | 1252 | (52.7) | 277 | (56.1) | |
| 1 | 81 | (17.1) | 12 | (30.8) | 385 | (16.2) | 116 | (23.5) | |
| 2 | 101 | (21.3) | 13 | (33.3) | 483 | (20.3) | 61 | (12.3) | |
| ≥3 | 121 | (25.5) | 6 | (15.4) | 255 | (10.7) | 40 | (8.1) | |
| Polypharmacy (5 or more) | N = 474 | N = 38 | N = 2375 | N = 476 | <0.001 | ||||
| No | 215 | (45.4) | 12 | (31.6) | 1383 | (58.2) | 283 | (59.5) | |
| Yes | 259 | (54.6) | 26 | (68.4) | 992 | (41.8) | 193 | (40.5) | |
| BMI | N = 309 | N = 38 | N = 2017 | N = 493 | <0.001 | ||||
| <18.5 | 15 | (4.9) | 0 | (0.0) | 19 | (0.9) | 4 | (0.8) | |
| 18.5–25 | 103 | (33.3) | 18 | (47.4) | 624 | (30.9) | 176 | (35.7) | |
| 25-30 | 113 | (36.6) | 15 | (39.5) | 767 | (38.0) | 197 | (40.0) | |
| >30 | 78 | (25.2) | 5 | (13.2) | 607 | (30.1) | 116 | (23.5) | |
| Nutritional risk score (MUST) | N = 297 | N = 35 | N = 1944 | N = 447 | <0.001 | ||||
| Low risk | 239 | (80.5) | 30 | (85.7) | 1703 | (87.6) | 413 | (92.4) | |
| Medium risk | 28 | (9.4) | 5 | (14.3) | 150 | (7.7) | 23 | (5.1) | |
| High risk | 30 | (10.1) | 0 | (0.0) | 91 | (4.7) | 11 | (2.5) | |
| Mental status (MMSE) | N = 286 | N = 37 | N = 1664 | N = 464 | <0.001 | ||||
| vNormal (≥24) | 246 | (86.0) | 34 | (91.9) | 1607 | (96.6) | 449 | (96.8) | |
| Impaired (<24) | 40 | (14.0) | 3 | (8.1) | 57 | (3.4) | 15 | (3.2) | |
| Functional status (Barthel)c | N = 395 | N = 39 | N = 2167 | N = 492 | <0.001 | ||||
| Independent | 324 | (82.0) | 25 | (64.1) | 2123 | (98.0) | 448 | (91.1) | |
| Partially or minimally dependent | 59 | (14.9) | 12 | (30.8) | 43 | (2.0) | 35 | (7.1) | |
| Very or fully dependent | 12 | (3.0) | 2 | (5.1) | 1 | (0.0) | 9 | (1.8) | |
| Mean | 72.1 | 60.8 | 78.6 | 74.9 | <0.001 | ||||
a
Missing numbers are not presented in this table.
b
Clinical tumour size or nodal status, if unavailable, pathological tumour size or nodal status was used.
c
Barthel: excluding questions on controlling bladder and bowel (absent in climb dataset).